Reprise Biomedical
Plymouth, US · Founded 2019 · Minnesota corporation
Reprise Biomedical develops and commercializes biologic medical devices using a proprietary perfusion decellularization process for surgical applications. The company serves physicians and healthcare providers delivering medical devices for a range of surgical procedures.
Founders & leadership
JI
Jake IsenburginExecutive
CP
Carrie PowersinPresident and Chief Executive Officer
TK
Tom KouchoukosExecutive
JK
Jerrod KruegerinExecutive
JD
Jeff DuncaninExecutive
SJ
Steve JagodzinskiinExecutive
HK
Heather KotilainExecutive
Board
RE
Ronald EibensteinerBoard director
EK
Erwin KelenBoard director
PN
Phil NalboneBoard director
HR
Howard RootBoard director
AW
Alan WoldtBoard director
Reported raises · per SEC filings
Form D private placements$56.4M disclosed across 6 rounds · 2019–2026
▶$9.2MraisedJul 2026 · 43 investors · BiotechnologyRule 506(b)
▶$9.2MraisedJul 2026 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carrie PowersExecutive Officer, Director
- Jake IsenburgExecutive Officer
- Tom KouchoukosExecutive Officer
- Steve JagodzinskiExecutive Officer
- Greg SmockExecutive Officer
- Jerrod KruegerExecutive Officer
- Heather KotilaExecutive Officer
- Howard RootDirector
- Ronald EibensteinerDirector
- Erwin KelenDirector
- Phil NalboneDirector
- Alan WoldtDirector
- Jeff DuncanExecutive Officer
- Offering amount
- $10M
- Amount sold
- $9.2M
- Placement agents
- Cedar Point Capital, LLC
- First sale
- May 2026
- Incorporated
- Corporation, Minnesota
- Federal exemptions
- 06b
▶$6.4MraisedJul 2025 · 14 investors · BiotechnologyRule 506(b)
▶$6.4MraisedJul 2025 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jake IsenburgExecutive Officer
- Carrie PowersExecutive Officer, Director
- Ronald EibensteinerDirector
- Phil NalboneDirector
- Howard RootDirector
- Tom KouchoukosExecutive Officer
- Erwin KelenDirector
- Alan WoldtDirector
- Jerrod KruegerExecutive Officer
- Jeff DuncanExecutive Officer
- Steve JagodzinskiExecutive Officer
- Heather KotilaExecutive Officer
- Greg SmockExecutive Officer
- Offering amount
- $7M
- Amount sold
- $6.4M
- Sales commissions
- $445K
- Placement agents
- Cedar Point Capital, LLC
- First sale
- Jun 2025
- Incorporated
- Corporation, Minnesota
- Federal exemptions
- 06b
▶$8MraisedDec 2023 · 77 investors · BiotechnologyRule 506(b)
▶$8MraisedDec 2023 · 77 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Erwin KelenDirector
- Tina WaltersExecutive Officer
- Jerrod KruegerExecutive Officer
- Phil NalboneDirector
- Steve JagodzinskiExecutive Officer
- Greg SmockExecutive Officer
- Ronald EibensteinerDirector
- Jake IsenburgExecutive Officer
- Carrie PowersExecutive Officer, Director
- Heather KotilaExecutive Officer
- Howard RootDirector
- Offering amount
- $12.5M
- Amount sold
- $8M
- Placement agents
- Cedar Point Capital, LLC
- First sale
- Oct 2023
- Incorporated
- Corporation, Minnesota, 2019
- Federal exemptions
- 06b
▶$15.3MraisedJan 2023 · 64 investors · BiotechnologyRule 506(b)
▶$15.3MraisedJan 2023 · 64 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- RONALD EIBENSTEINERDirector
- PHILLIP NALBONEDirector
- CARRIE POWERSExecutive Officer, Director
- ERWIN KELENDirector
- PHIL NALBONEDirector
- HOWARD ROOTExecutive Officer, Director
- Offering amount
- $15.3M
- Amount sold
- $15.3M
- First sale
- Dec 2022
- Incorporated
- Corporation, Minnesota, 2019
- Federal exemptions
- 06b
▶$5MraisedMar 2021 · 39 investors · BiotechnologyRule 506(b)
▶$5MraisedMar 2021 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- CARRIE POWERSExecutive Officer, Director
- RONALD EIBENSTEINERDirector
- ERWIN KELENDirector
- JEFF ROSSDirector
- HOWARD ROOTExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Nov 2020
- Incorporated
- Corporation, Minnesota, 2019
- Federal exemptions
- 06b
▶$12.5MraisedJul 2019 · 51 investors · BiotechnologyRule 506(b)
▶$12.5MraisedJul 2019 · 51 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carrie PowersExecutive Officer, Director
- Howard RootDirector
- Jeff RossDirector
- Erwin KelenDirector
- Ronald EibensteinerDirector
- Offering amount
- $12.5M
- Amount sold
- $12.5M
- First sale
- Jun 2019
- Incorporated
- Corporation, Minnesota, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Organogenesis26 shared keywordsOrganogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.
Aroa18 shared keywordsAroa Biosurgery Limited manufactures medical devices, including Endoform, for surgical applications with coverage under Medicare reimbursement policies.
Globus Medical17 shared keywordsGlobus Medical designs and manufactures spine, trauma, and robotic surgical products for the orthopedic medical device market. The company serves hospitals and surgical centers globally.
Companies competing with Reprise Biomedical for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Reprise Biomedical do?
- Reprise Biomedical develops and commercializes biologic medical devices using a proprietary perfusion decellularization process for surgical applications. The company serves physicians and healthcare providers delivering medical devices for a range of surgical procedures.
- How much funding has Reprise Biomedical raised?
- Reprise Biomedical has disclosed $56.4M raised across 6 rounds.
- Where is Reprise Biomedical headquartered?
- Reprise Biomedical is headquartered in Plymouth, US.